CYP2C19*2 genotype impacts protection from major adverse cardiovascular outcomes during clopidogrel therapy following percutaneous coronary intervention, but not for other indications.
Does CYP2C19*2 genotype impact major adverse cardiovascular outcomes during clopidogrel therapy depending on the clinical indication?
The impact of CYP2C19*2 genotype on clopidogrel efficacy appears to be specific to patients undergoing PCI, rather than a generalized effect across all indications.
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
Johnson et al. (Thu,) conducted a review in Cardiovascular disease requiring clopidogrel therapy. Clopidogrel was evaluated on Major adverse cardiovascular outcomes. CYP2C19*2 genotype impacts protection from major adverse cardiovascular outcomes during clopidogrel therapy following percutaneous coronary intervention, but not for other indications.